N@N

Telik Inc (NASDAQ:TELK), Up By 83.73% ($1.39) From $1.660 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Co

^{Published on 2013-02-06 07:47:15 - WOPRAI}
 

February 6, 2013 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Tuesday, February 5th 2013 stating that Telik Inc (NASDAQ:TELK) was expected to go Up due to the Bullish conditions presented in the following report. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=telk&id=345557

At the time this story was written, Telik Inc (NASDAQ:TELK) is Up By $1.39 (83.73%) since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following specific fundamental or technical events may follow a predictable pattern. Many companies stock price histories show random or unpredictable movements around certain events. But some seem to repeat the same pattern quarter after quarter, year after year. We use powerful computers to uncover those events and correlations to generate predictions with high probabilities of generating very specific returns within very specific time periods.

The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

Telik Inc (NASDAQ:TELK) - Telik, Inc., a clinical-stage drug development company, engages in the discovery and development of small molecule drugs to treat cancer. Its lead drug product candidate in clinical development, TELINTRA, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1, which is under Phase II clinical trial for the treatment of blood disorders associated with low blood cell levels, such as neutropenia or anemia. The company is also developing TELCYTA, a cancer cell-activated chemotherapeutic, which has been in multiple Phase II and Phase III trials in patients with advanced ovarian cancer, non-small cell lung cancer, colon cancer, and breast cancer. Its preclinical drug product developments include TLK60404, a small molecule compound, which inhibits both Aurora kinase and VEGFR kinase; TLK60357, a novel, small molecule inhibitor of cell division; and TLK60596, a VGFR kinase inhibitor that blocks the formation of new blood vessels in tumors. The company s product candidates are discovered using its proprietary technology, target-related affinity profiling (TRAP), which enables the discovery of small molecule product candidates. Telik, Inc. was founded in 1988 and is based in Palo Alto, California.. There is a failure to deliver in shares of TELK

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor market-maker surveillance system tracking Level II market-makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 30 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies specifically for this report, but may have been compensated up to $1,200 per month in the past for unrelated data or report services. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net